Biogen’s Alzheimer’s Drug: Boon Or Bust?

Was the latest data on its experimental Alzheimer’s drug good news for Biogen ( BIIB )? It’s a legitimate question given how the drug maker’s stock has performed today. At a recent $287.18, the shares are down 0.8%, giving back earlier gains. The stock had at one point climbed more than 6% to just under $307 a share. What gives? To be sure, there is certainly some “sell the news” going on here. But there are also safety questions that need to be addressed following news that one patient in the Biogen study experienced a treatment related seizure and a loss of pulse.